The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48. The EORTC QLQMyeloma module (EORTC QLQ-MY20) demonstrated initial improvements and subsequent stabilization of disease symptom scores in both arms and initial worsening and subsequent improvement of side effects of treatment scores, with the initial worsening more pronounced and recovery less pronounced with PAN + BTZ + DEX. Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scores remained relatively stable and similar between the arms. Overall, these PRO findings support the addition of PAN to the BTZ+DEX regimen as an efficacious treatment option, with limited symptomatology and impact on patients' QoL. The reported results are based on a descriptive analysis of the data. No formal statistical tests have been performed.
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Multiple myeloma (MM) is a B cell malignancy of terminally differentiated plasma cells, that accounts for about 10% of all haematological malignancies and follows a characteristic remitting and relapsing pattern (Katzel et al, 2007; Dimopoulos & Terpos, 2010) . Although MM remains incurable, patients with relapsed (i.e., response to therapy with subsequent progression beyond 60 days of the last therapy [Rajkumar, 2011; ] ) or refractory multiple myeloma (RRMM) are living longer due to survival gains that are being achieved with newer therapies, which include proteasome inhibitors and immunomodulatory drugs (IMiDs) (Kumar et al, 2014) .
The impact of disease symptoms on health-related quality of life (HRQoL) for patients with MM is well documented (Mols et al, 2012; van der Poel et al, 2015; Kiely et al, 2016) . Specifically, MM patients experience deterioration of function and global health status, along with increased fatigue, pain, and dyspnea due to their disease (van der Poel et al, 2015; Kiely et al, 2016) . Patients also experience significant emotional and mental stress as a result of their disease, which is linked to financial worries, anxiety and depression (Kiely et al, 2016) . From a patient perspective, MM-related issues of particular importance include disease-related symptoms, such as pain and fatigue, which have a notable impact on physical functioning. Additionally, treatmentrelated side effects and other issues (e.g., body image, perspective of the future) may affect patient-reported measures of functioning, HRQoL and well-being (Stead et al, 1999; Cocks et al, 2007) . As such, treatment-related toxicities may compound disease symptoms and cause even greater patient distress and affect the everyday life of patients. For example, neurotoxicity is a known side effect associated with treatment with bortezomib (BTZ), the most commonly used backbone in the treatment of RRMM (Badros et al, 2007) . This BTZ-induced neuropathy, a dose-limiting side effect with a potentially high impact on functioning and HRQoL, can be a significant concern to physicians and patients (Badros et al, 2007; Ghobrial et al, 2011) . Considering that BTZ is a timetested treatment administered for a limited duration of therapy, strategies to enhance its efficacy in later lines without compromising tolerability may be potentially valuable and therefore of interest to physicians and patients. BTZ is associated with improvement in objective measures of efficacy; however, effective treatments must not compromise HRQoL experienced by patients. Therefore, assessment of patientreported outcomes (PROs) has become a critical component of contemporary clinical trials.
Panobinostat (PAN), in combination with BTZ and dexamethasone (DEX), is approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of MM patients who have received ≥2 prior regimens, including BTZ and an IMiD. This approval was based on the significant clinical benefit of PAN + BTZ + DEX in the phase 3, placebo (PBO)-controlled PANORAMA-1 trial in patients with RRMM (San-Miguel et al, 2014; Richardson et al, 2016) . The FDA and EMA approvals of PAN were based on the efficacy and safety in a subset of patients who had previously received ≥2 prior regimens that had included BTZ and an IMiD . In this subset of 147 patients, the difference in median progression-free survival (PFS) was 12Á5 months with PAN + BTZ + DEX versus 4Á7 months with PBO + BTZ + DEX, for a hazard ratio (HR) of 0Á47 (95% confidence interval [CI]: 0Á31, 0Á72). The safety profile of PAN + BTZ + DEX was similar across different subgroups based on prior treatment (i.e., prior IMiD, prior BTZ + IMiD and ≥2 prior regimens including BTZ and IMiD), with diarrhoea, fatigue/asthenia, and peripheral neuropathy as the most commonly reported side effects.
This analysis provides a detailed assessment of the patient experience with PAN + BTZ + DEX in PANORAMA-1 based on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), the EORTC QLQ-Myeloma module (EORTC QLQ-MY20), and the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-Neurotoxicity (FACT/ GOG-Ntx), commonly used PRO measures in oncology, with a focus on disease-and treatment-related symptoms that are most commonly reported among patients with RRMM. The overarching objective was to explore the patient experience in PANORAMA-1, specifically within the subset of patients who had received ≥2 prior regimens (including BTZ and an IMiD), based on PRO measures of symptoms, functioning and HRQoL.
Methods
The methodology of the PANORAMA-1 trial is described in detail by San-Miguel et al (2014) and Richardson et al (2016) . Briefly, patients with RRMM who had received 1-3 previous treatment regimens were randomized 1:1 to PBO or PAN in combination with BTZ + DEX. There were 2 treatment phases, each lasting 24 weeks. In treatment phase 1, PAN 20 mg or PBO were taken orally on days 1, 3, 5, 8, 10 and 12. All patients received 1 dose of BTZ 1Á3 mg/m 2 intravenously on days 1, 4, 8 and 11 and 2 doses of DEX 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12. After 8 cycles (or 24 weeks), patients with clinical benefit (i.e., at least no change in disease status) proceeded to treatment phase 2, during which patients received PAN or PBO (same schedule), BTZ (reduced to once weekly during weeks 1, 2, 4 and 5), and DEX (on the day of and after BTZ) every 6 weeks for 4 cycles. The EORTC QLQ-C30 (Fayers, 2001) , EORTC QLQ-MY20 (Cocks et al, 2007) , and FACT/GOG-Ntx (Calhoun et al, 2003) were administered at screening; cycle 1, day 1; and every 6 weeks thereafter until end of treatment. The EORTC QLQ-C30 is a general cancer-specific QoL and functioning measure that includes 5 functional scales (physical, role, social, emotional, cognitive); 3 symptom scales (fatigue, pain, nausea/vomiting); 2 global health status/QoL items, and 6 other items (dyspnoea, sleep, appetite, constipation, diarrhoea, financial worry). The EORTC QLQ-MY20 is a myeloma-specific QoL measure with 4 subscales (disease-related symptoms, treatment-related adverse events [AEs] , body image and future perspective). EORTC QLQ-C30 and EORTC QLQ-MY20 include 30 and 20 self-administered questions, respectively, both using a recall period of "the past week," with subscale scores ranging from 0 to 100 (higher QoL or functioning scores indicate better QoL or functioning, but higher symptom scores indicate more symptom problems). The FACT/GOG-Ntx was designed to assess treatment-related neurotoxicity using 5 subscales ( administered questions are based on a recall period of "the past 7 days," with higher scores indicating better outcomes. The FACT/GOG-Ntx was scored according to previously described methodology (Fayers, 2001; Calhoun et al, 2003) .
For each treatment group, calculated subscale scores were summarized descriptively using means and standard deviations by time window up to the end of 48 weeks, including the 24-week treatment phase 1 and the subsequent 24-week treatment phase 2.
Results

Patient population
PROs were assessed for 147 patients who received both BTZ and an IMiD and ≥2 lines of therapy, including 73 patients in the PAN + BTZ + DEX arm and 74 patients in the PBO + BTZ + DEX arm. Baseline characteristics for these patients are summarized in Table I . Median age (61 years for both groups) and the extent of prior treatment did not differ between the 2 arms, for which the types of prior treatments and stage were also generally similar. More males received PAN + BTZ + DEX compared to PBO + BTZ+DEX; additionally, the most common Eastern Cooperative Oncology Group (ECOG) performance status was 0 and ≥1 in the PAN + BTZ + DEX and PBO + BTZ + DEX arms, respectively.
In general, mean baseline scores of EORTC QLQ-C30, EORTC QLQ-MY20 and FACT/GOG-Ntx scales/subscales were well balanced between the PAN + BTZ + DEX and PBO + BTZ + DEX arms (Tables II-IV) .
EORTC QLQ-C30
EORTC QLQ-C30 scores at baseline, Week 24 and Week 48 are summarized in Table II . Global health status/QoL scores of the QLQ-C30 initially declined in the PAN + BTZ+DEX arm during the study treatment period before returning back toward baseline scores and remaining steady during treatment phase 2, with no difference between arms at Week 48 (Fig 1) . In general, functioning scale scores remained moderately high throughout the study, with slight declines seen in some subscales for both treatment arms (Table II) . For physical functioning, scores fell from baseline to Week 48 with PBO + BTZ + DEX (from 68Á21 to 60Á00 [indicating a worsening of function]), but not with PBO + BTZ + DEX (from 72Á68 to 72Á67). With PAN + BTZ + DEX, the largest functioning scale score reductions from baseline to Week 48 occurred with respect to emotional, cognitive and social function; however, the score reductions were smaller than those seen with PBO + BTZ + DEX. Most EORTC QLQ-C30 symptom scales showed some degree of worsening with PAN + BTZ + DEX, most notably with respect to diarrhoea and appetite loss, with treatment effects also seen with PBO + BTZ + DEX.
EORTC QLQ-MY20
EORTC QLQ-MY20 scores at baseline, Week 24 and Week 48 are summarized in Table III . Disease symptom scores indicated an initial improvement from baseline to Week 24 and subsequent stabilization in both treatment arms, with the exception of 1 outlier value at Week 48 for PAN + BTZ + DEX (Fig 2) . In general, side effects of treatment scores initially worsened (as reflected by higher scores) from baseline to Week 24 in both arms, although more so with PAN + BTZ + DEX (from 17Á58 to 32Á11) than with PBO + BTZ + DEX (from 19Á32 to 21Á11); subsequently, scores trended toward improvement (as reflected by lower scores) for both treatment arms, with a larger recovery seen in the PBO + BTZ + DEX based on Week 48 scores (9Á38 with PBO + BTZ + DEX and 27Á04 with PAN + BTZ + DEX). In both arms, body image scores at Weeks 24 and 48 were lower than those at baseline. Future perspective scores suggested directional improvement over the first 24-week treatment period with both PAN + BTZ + DEX (61Á59 at baseline to 66Á67 at Week 24) and PBO + BTZ + DEX (53Á97 at baseline to 64Á29 at Week 24), with worsening from Week 24 to Week 48 that was notably more pronounced with PBO + BTZ + DEX (to a Week 48 score of 37Á04, compared with 51Á11 for PAN + BTZ + DEX).
FACT-GOG-Ntx
FACT/GOG-Ntx scores at baseline, Week 24 and Week 48 are summarized in Table IV . FACT/GOG-Ntx well-being subscales were generally stable over the study period for both treatment arms and also generally similar between the 2 treatment arms. Neurotoxicity subscale scores remained relatively stable in both arms during both treatment periods, with some improvement in the PBO + BTZ + DEX arm starting at Week 24 (Fig 3) .
Discussion
These PRO findings from a placebo-controlled phase 3 registration trial support the addition of PAN to the well-established BTZ + DEX regimen as an efficacious treatment option, with limited symptomatology and impact on patients' HRQoL. With the increasing importance of patient-relevant humanistic benefits in determining the overall value of oncology products, as seen in the recent American Society of Clinical Oncology (ASCO) Value Framework (Schnipper et al, 2015 (Schnipper et al, , 2016 , findings such as those reported here are important for treatment decision-making. Although the ASCO acknowledges that clinical benefit represents a combination of both disease-specific treatment effectiveness and HRQoL/PRO assessments, they found a lack of consistency and reliability with reporting of the later outcomes within clinical trials, with determination of the overall health benefit of treatment derived primarily from high-grade acute toxicity (which is unlikely to reflect overall health status).
Overall, the findings from the PANORAMA-1 study are similar to those seen in other studies of BTZ-based regimens, suggesting a limited impact on overall patient HRQoL with the use of clinically effective BTZ-containing regimens for RRMM (Lee et al, 2008; Sonneveld et al, 2013) . For example, per prospective evaluation of HRQoL using both the EORTC QLQ-30 and the FACT/GOG-Ntx within the APEX trial (a phase 3 comparison of BTZ vs DEX for RRMM), significant differences in EORTC QLQ-30 global health status (and physical health, role, cognitive, and emotional functioning) and FACT/GOG-Ntx total scores favoured BTZ, with a sensitivity analysis suggesting that these results were explained, at least in part, by the improved survival outcomes with BTZ in the APEX trial (Lee et al, 2008) . As noted by the APEX investigators, considering that BTZ produces a higher incidence of grade ≥2 neurotoxicity relative to high-dose DEX, FACT/ GOG-Ntx scores may have favoured BTZ due to the inclusion of questions in the FACT/GOG-Ntx that do not specifically pertain to chemotherapy-induced peripheral neuropathy. In our analysis, FACT/GOG-Ntx well-being subscales were generally stable and similar between the 2 treatment arms. The greater declines with PAN + BTZ + DEX, with respect to the EORTC QLQ-C30 symptom scales, were likewise consistent with the known AE profile of PAN + BTZ + DEX, which has been shown to increase the incidences of both all-grade and grade 3/4 diarrhoea (76% and 33%, respectively, compared with 47% and 15%, respectively, with PBO + BTZ + DEX) and fatigue/asthenia (60% and 26%, respectively, compared with 49% and 14% with PBO + BTZ + DEX) . Importantly, the safety profile of PAN + BTZ + DEX does not appear to be influenced by the extent or types of prior treatments, and AEs such as diarrhoea are generally transient and manageable with appropriate supportive measures (e.g., with use of loperamide). Considering that QLQ-C30-derived global health status/QoL scores improved in the PAN + BTZ + DEX arm during treatment phase 2, and ultimately were no different than those with PBO + BTZ + DEX at Week 48, these toxicities may have been offset by improvements in disease-related outcomes. It is important to keep in mind that the PRO data were collected only during treatment periods. Although HRQoL showed an initial decline during active treatment, which could be partly attributed to treatment-related toxicity, limited post-treatment data (not shown) suggest that patients' HRQoL post-treatment was similar to baseline levels; however, conclusions cannot be reached due to minimal data. , is offset by improvements in disease-related symptoms and prolonged progression-free and overall survival requires further studies with prolonged patient follow-up over a period of several years. Additionally, accumulating evidence also points toward the ability to improve on the tolerability of established combination regimens for MM, such as by extending the dosing interval for BTZ to once-weekly administration (Bringhen et al, 2010; Girnius et al, 2015; Totani et al, 2016) . PAN, dosed at 10 mg, is being explored with lenalidomide + BTZ + DEX (RVD regimen) based on phase I/II data in the induction setting (Shah et al, 2015) , as promising efficacy and tolerability data for combining PAN with the selective proteasome inhibitor carfilzomib also emerge (Berdeja et al, 2015) . At the same time, clinical trials of more selective histone deacetylase (HDAC) inhibitors (e.g., the HDAC6 inhibitors ricolinostat [Yee et al, 2016] and ACY-241 [Yee et al, 2016; Quayle et al, 2015] ) as a component of MM regimens are underway. Given the intense research efforts to identify not only more effective but also more tolerable MM regimens, HRQoL assessments should be regarded as an essential component of their ongoing development.
The analysis of PRO data was not a primary or a key secondary objective of the study and, thus, the study was not powered for testing PRO endpoints. While a formal analysis (including repeated measures analysis) was indeed planned and completed (and included in the clinical study report) for the full analysis set of 768 RRMM patients from the PANORAMA-1 trial (San-Miguel et al, 2014; Richardson et al, 2016) , such an extensive, unplanned, post-hoc analysis was not deemed appropriate for the much smaller subset of 147 patients reflecting the approved label population. More precisely, the main purpose of this manuscript is to inform the overall risk-benefit assessment for the population of patients for which the drug has been approved. Thus, the results of the analysis of the PRO data for the full analysis set of 768 patients are not directly relevant to this objective and are not being reported here. Further, we acknowledge several limitations of our findings, including the relatively small sample sizes and descriptive nature of the analyses, but believe that they still add value to the assessment of risk-benefit for potential patients for this treatment.
Additionally, there were some imbalances between the arms with respect to baseline characteristics (which may be a reflection of the subset of 147 patients), most notably for gender and ECOG performance status. Additional limitations include those that are inherent to PRO analyses that are derived from self-reported assessment of subjective measures. The lack of established guidelines for collecting and analysing PRO data in MM complicates comparisons with results from other studies (Sonneveld et al, 2013) .
Conclusion
In conclusion, the results from the descriptive analysis reported here suggest that combination treatment of PAN + BTZ + DEX has a similar impact on HRQoL as PBO + BTZ + DEX, with recovery and stabilization of HRQoL after an initial decline during the early treatment period. Furthermore, accumulating evidence points towards improvements in the tolerability of established combination regimens by extending the dosing interval for BTZ, combining PAN with the selective proteasome inhibitor carfilzomib, or through the inclusion of more selective HDAC inhibitors as a component of MM regimens.
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